Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 3
2002 12
2003 7
2004 12
2005 27
2006 22
2007 22
2008 17
2009 17
2010 37
2011 50
2012 50
2013 52
2014 51
2015 53
2016 58
2017 55
2018 58
2019 38
2020 63
2021 64
2022 68
2023 89
2024 105
2025 125
2026 96

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,128 results

Results by year

Filters applied: . Clear all
Page 1
Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children: INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical Trials.
Simpson EL, Eichenfield LF, Alonso-Llamazares J, Draelos ZD, Ferris LK, Forman SB, Gooderham M, Gonzalez ME, Hebert AA, Kircik LH, Lomaga M, Moore A, Papp KA, Prajapati VH, Hanna D, Snyder S, Krupa D, Burnett P, Almaraz E, Higham RC, Chu DH, Berk DR. Simpson EL, et al. JAMA Dermatol. 2024 Nov 1;160(11):1161-1170. doi: 10.1001/jamadermatol.2024.3121. JAMA Dermatol. 2024. PMID: 39292443 Free PMC article. Clinical Trial.
OBJECTIVE: To evaluate efficacy and safety of once-daily roflumilast cream, 0.15%, vs vehicle cream in patients with AD. DESIGN, SETTING, AND PARTICIPANTS: Two phase 3, randomized, double-blind, vehicle-controlled trials (Interventional Trial Evaluating Roflumilast …
OBJECTIVE: To evaluate efficacy and safety of once-daily roflumilast cream, 0.15%, vs vehicle cream in patients with AD. DESIGN, SETT …
Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.
Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF. Martinez FJ, et al. Lancet. 2015 Mar 7;385(9971):857-66. doi: 10.1016/S0140-6736(14)62410-7. Epub 2015 Feb 13. Lancet. 2015. PMID: 25684586 Clinical Trial.
BACKGROUND: Roflumilast reduces exacerbations in patients with severe chronic obstructive pulmonary disease. ...Adverse events were reported by 648 (67%) of 968 patients receiving roflumilast and by 572 (59%) of 967 patients in the placebo group; adverse event-assoc …
BACKGROUND: Roflumilast reduces exacerbations in patients with severe chronic obstructive pulmonary disease. ...Adverse events were r …
Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body: The ARRECTOR Phase 3 Randomized Clinical Trial.
Gooderham MJ, Alonso-Llamazares J, Bagel J, Bhatia N, Bukhalo M, DuBois J, Ferris LK, Green L, Kircik LH, Lockshin B, Loo WJ, Papp KA, Soung J, Seal MS, Snyder S, Kato S, Krupa D, Burnett P, Berk DR, Chu DH. Gooderham MJ, et al. JAMA Dermatol. 2025 Jul 1;161(7):698-706. doi: 10.1001/jamadermatol.2025.1136. JAMA Dermatol. 2025. PMID: 40332898 Free PMC article. Clinical Trial.

RESULTS: A total of 432 patients (mean [SD] age, 47.3 [14.8] years; 243 women [56.3%]) were randomized to roflumilast foam (n = 281) or vehicle (n = 151). At week 8, 66.4% of the roflumilast group achieved S-IGA success vs 27.8% of the vehicle group (P < .001); a

…
RESULTS: A total of 432 patients (mean [SD] age, 47.3 [14.8] years; 243 women [56.3%]) were randomized to roflumilast foam (n = 281) …
Roflumilast.
[No authors listed] [No authors listed] Am J Health Syst Pharm. 2022 Nov 22;79(23):2086-2087. doi: 10.1093/ajhp/zxac249. Am J Health Syst Pharm. 2022. PMID: 36197808 No abstract available.
Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials.
Lebwohl MG, Kircik LH, Moore AY, Stein Gold L, Draelos ZD, Gooderham MJ, Papp KA, Bagel J, Bhatia N, Del Rosso JQ, Ferris LK, Green LJ, Hebert AA, Jones T, Kempers SE, Pariser DM, Yamauchi PS, Zirwas M, Albrecht L, Devani AR, Lomaga M, Feng A, Snyder S, Burnett P, Higham RC, Berk DR. Lebwohl MG, et al. JAMA. 2022 Sep 20;328(11):1073-1084. doi: 10.1001/jama.2022.15632. JAMA. 2022. PMID: 36125472 Free PMC article.
The incidence of treatment-emergent adverse events was 25.2% with roflumilast vs 23.5% with vehicle in trial 1 and 25.9% with roflumilast vs 18.4% with vehicle in trial 2. The incidence of serious adverse events was 0.7% with roflumilast vs 0.7% with vehicle …
The incidence of treatment-emergent adverse events was 25.2% with roflumilast vs 23.5% with vehicle in trial 1 and 25.9% with rofl …
Efficacy and Safety of Once-Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2-5 Years With Mild-to-Moderate Atopic Dermatitis (INTEGUMENT-PED): A Phase 3 Randomized Controlled Trial.
Eichenfield LF, Serrao R, Prajapati VH, Browning JC, Swanson L, Funk T, Gonzalez ME, Hebert AA, Lee M, Boguniewicz M, Simpson EL, Seal MS, Krupa D, Hanna D, Snyder S, Burnett P, Chu DH, Almaraz E, Higham RC, Berk DR. Eichenfield LF, et al. Pediatr Dermatol. 2025 Mar-Apr;42(2):296-304. doi: 10.1111/pde.15840. Epub 2025 Feb 20. Pediatr Dermatol. 2025. PMID: 39980188 Free PMC article. Clinical Trial.
This Phase 3 parallel-group, double-blind trial (INTEGUMENT-PED; NCT04845620) compared the efficacy and safety of roflumilast cream 0.05% and a vehicle in patients aged 2-5 years with AD. METHODS: Patients aged 2-5 years with mild-to-moderate AD were treated with once-dail …
This Phase 3 parallel-group, double-blind trial (INTEGUMENT-PED; NCT04845620) compared the efficacy and safety of roflumilast cream 0 …
Innovations in Psoriasis.
Martin A, Ibraheim MK, Gupta R, Wu JJ. Martin A, et al. Dermatol Clin. 2025 Jan;43(1):1-9. doi: 10.1016/j.det.2024.08.001. Epub 2024 Sep 10. Dermatol Clin. 2025. PMID: 39542556 Review.
This review discusses therapies that were recently Food and Drug Administration (FDA)-approved for treating psoriasis, including the topical agents tapinarof and roflumilast, deucravacitinib, an oral small molecule that selectively inhibits tyrosine kinase 2, and spesolima …
This review discusses therapies that were recently Food and Drug Administration (FDA)-approved for treating psoriasis, including the topical …
Roflumilast for Oral Ulcers in Behcet's Disease and Recurrent Aphthous Stomatitis.
Chung KB, Sung HJ, Kim EH, Jang H, Kim DY. Chung KB, et al. J Dermatol. 2025 Nov;52(11):1713-1717. doi: 10.1111/1346-8138.17972. Epub 2025 Sep 23. J Dermatol. 2025. PMID: 40985567 Free PMC article.
Among the cohort, 78.3% of patients tolerated roflumilast without discontinuation, including 15.2% with dose reduction, while 21.7% discontinued due to intolerable AEs. Roflumilast demonstrated rapid and sustained efficacy in reducing OUs in BD and RAS. Although AEs …
Among the cohort, 78.3% of patients tolerated roflumilast without discontinuation, including 15.2% with dose reduction, while 21.7% d …
Roflumilast for asthma: Weighing the evidence.
Bateman ED, O'Byrne PM, Buhl R, Rabe KF. Bateman ED, et al. Pulm Pharmacol Ther. 2015 Dec;35 Suppl:S1-3. doi: 10.1016/j.pupt.2015.08.001. Epub 2015 Aug 13. Pulm Pharmacol Ther. 2015. PMID: 26278190 No abstract available.
Topical Roflumilast for Plaque Psoriasis.
O'Toole A, Gooderham M. O'Toole A, et al. Skin Therapy Lett. 2023 Sep;28(5):1-4. Skin Therapy Lett. 2023. PMID: 37734074 Free article. Review.
Roflumilast is a highly selective phosphodiesterase-4 inhibitor for the treatment of plaque psoriasis. ...Herein, we review the safety and efficacy of roflumilast 0.3% cream, as demonstrated in clinical trials....
Roflumilast is a highly selective phosphodiesterase-4 inhibitor for the treatment of plaque psoriasis. ...Herein, we review the safet …
1,128 results